FDA Approves METHYLPHENIDATE — Mylan Pharmaceuticals Inc.

Mylan Pharmaceuticals Inc. has secured FDA approval for its ANDA206497, granting market access to the transdermal form of methylphenidate, a critical development that expands competition in the multi-billion dollar therapeutic space for stimulant delivery systems. This approval positions the generic manufacturer to disrupt the existing market landscape of branded skin patches, offering a potential alternative and influencing price dynamics within the CNS stimulant sector.